Follow
Isabel Machin Díaz
Isabel Machin Díaz
Lab Manager, Laboratorio Neuroinmuno-Reparación, Hospital Nacional de Parapléjicos
Verified email at sescam.jccm.es
Title
Cited by
Cited by
Year
NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients
S Malhotra, C Costa, H Eixarch, CW Keller, L Amman, ...
Brain 143 (5), 1414-1430, 2020
1062020
2‐AG limits Theiler's virus induced acute neuroinflammation by modulating microglia and promoting MDSCs
M Mecha, A Feliú, I Machín, C Cordero, F Carrillo‐Salinas, L Mestre, ...
Glia 66 (7), 1447-1463, 2018
412018
The presence and suppressive activity of myeloid-derived suppressor cells are potentiated after interferon-β treatment in a murine model of multiple sclerosis
C Melero-Jerez, M Suardíaz, R Lebrón-Galán, C Marín-Bañasco, ...
Neurobiology of disease 127, 13-31, 2019
322019
The proportion of myeloid-derived suppressor cells in the spleen is related to the severity of the clinical course and tissue damage extent in a murine model of multiple sclerosis
C Melero-Jerez, A Alonso-Gómez, E Moñivas, R Lebrón-Galán, ...
Neurobiology of disease 140, 104869, 2020
292020
Functional heterogeneity of mouse and human brain OPCs: relevance for preclinical studies in Multiple Sclerosis
FC Ana Bribián, Eva M. Medina-Rodríguez, Fernando Josa-Prado, Isabel García ...
Journal of Clinical Medicine 9 (6), 2020
272020
Tissue-type plasminogen activator exerts EGF-like chemokinetic effects on oligodendrocytes in white matter (re) myelination
C Leonetti, R Macrez, M Pruvost, Y Hommet, J Bronsard, A Fournier, ...
Molecular neurodegeneration 12, 1-16, 2017
162017
Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis
C Camacho-Toledano, I Machín-Díaz, L Calahorra, M Cabañas-Cotillas, ...
Journal of neuroinflammation 19 (1), 277, 2022
72022
Central and peripheral myeloid-derived suppressor cell-like cells are closely related to the clinical severity of multiple sclerosis
MC Ortega, R Lebrón-Galán, I Machín-Díaz, M Naughton, I Pérez-Molina, ...
Acta Neuropathologica 146 (2), 263-282, 2023
22023
Myeloid-Derived Suppressor Cells are relevant factors to predict the severity of multiple sclerosis
MC Ortega, R Lebrón-Galán, I Machín-Díaz, M Naughton, I Pérez-Molina, ...
bioRxiv, 2022.04. 20.488896, 2022
12022
Age-linked heterogeneity among oligodendrocyte precursor cells in the cerebral cortex of mice and human
A Bribián, EM Medina-Rodríguez, F Josa-Prado, I García-Álvarez, ...
bioRxiv, 799544, 2019
12019
Graphene oxide films as a novel tool for the modulation of myeloid-derived suppressor cell activity in the context of multiple sclerosis
C Camacho-Toledano, I Machín-Díaz, R Lebrón-Galán, ...
Nanoscale, 2024
2024
Circulating monocytic myeloid-derived suppressor cells but not Treg are potential biomarkers of a full relapse recovery in untreated multiple sclerosis patients
LC Melero, I Machin-Diaz, I Alonso-Garcia, IP Molina, ...
MULTIPLE SCLEROSIS JOURNAL 29, 562-563, 2023
2023
The first full histopathological description of monocytic myeloid-derived suppressor cells in the human brain: relationship to the severity of the clinical course in PPMS patients
MC Ortega Munoz, I Machin-Diaz, M Naughton, J Garcia-Arocha, ...
MULTIPLE SCLEROSIS JOURNAL 29, 468-469, 2023
2023
CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS AS A POTENTIAL BIOINDICATOR OF THE ENDOGENOUS MYELIN REPAIR CAPACITY IN EXPERIMENTAL MULTIPLE SCLEROSIS
MP Serrano-Regal, I Alonso-García, C Camacho-Toledano, I Machin-Diaz, ...
IBRO Neuroscience Reports 15, S290-S291, 2023
2023
MYELOID-DERIVED SUPPRESSOR CELL BURDEN IN THE CNS AND BLOOD IS ASSOCIATED WITH DISEASE SEVERITY OF MULTIPLE SCLEROSIS PATIENTS
MC Ortega, I Machin-Diaz, M Naughton, I Pérez-Molina, J García-Arocha, ...
IBRO Neuroscience Reports 15, S285-S286, 2023
2023
EVOBRUTINIB TREATMENT REDUCES THE DAMAGE TO THE CNS AND INCREASES THE NUMBER OF CLASSICAL DENDRITIC CELLS IN EXPERIMENTAL MULTIPLE SCLEROSIS
MP Serrano-Regal, L Calahorra, I Alonso-García, U Boschert, ...
IBRO Neuroscience Reports 15, S272-S273, 2023
2023
Evobrutinib therapeutic response is associated with an increase in the number and maturation of peripheral and central classical dendritic cells (P7-3.005)
D Clemente, MP Serrano-Regal, L Calahorra, I Alonso-García, ...
Neurology 100 (17 Supplement 2), 2023
2023
GRAPHENE OXIDE AS A NOVEL IMMUNOTHERAPY TOOL FOR THE MODULATION OF MYELOID-DERIVED SUPPRESSOR CELL ACTIVITY IN THE CONTEXT OF MULTIPLE SCLEROSIS
C Camacho-Toledano, I Machín-Díaz, R Lebrón-Galán, ...
bioRxiv, 2023.03. 28.534540, 2023
2023
Shedding light on the variability of the clinical course of multiple sclerosis: analysis of the influence of myeloidderived suppressor cells on disease severity
MC Ortega, J Garcia-Arocha, R Lebron-Galan, I Machin-Diaz, ...
MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 163-164, 2022
2022
Circulating myeloid-derived suppressor cells as a potential biomarker of an anti-inflammatory T-cell balance associated with improved relapse recovery in multiple sclerosis
L Calahorra, I Machin-Diaz, I Alonso, I Perez-Molina, ...
MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 829-829, 2022
2022
The system can't perform the operation now. Try again later.
Articles 1–20